Home

Primary Examiner: Rose, Shep K.
Assistant Examiner:
Attorney: Conte; Salvatore R.

Next ten patents ordered by date:

Process of stabilizing therapeutically useful plasmin solutions
Antibiotic TM-481 derived from microorganism of the streptomyces ribosidificus group
Animal feeds containing antibiotic AV290
Process for preparing cirramycin A.sub.1
Insulin derivatives
Composition and method of treating asthma
Asymmetric O,S-dialkyll-O-[(phenyl)-vinyl]-thlophosphates as insecticides
Administration of alkali metal salicylamide salts
Pharmaceutical compositions and methods of inhibiting gastric acid secretion
Pharmaceutical compositions containing a 5-oxo-2,3-dihydro-imidazo[1,2-a]-s-triazine and method of use

Translate:
En
De
Es
Fr
It
Pt
Ja
Ko
Zh

Title: Animal vaccines

Do you think this is a good invention? Vote now:

Votes so far: For:(0) Against:(0)
Claims: What is claimed is:

1. A vaccine useful in immunizing dogs against kennel cough comprising at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

2. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

3. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

4. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

5. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

6. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10 .sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunity.

7. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered nonpathogenic without loss of immunogenicity.

8. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

9. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine prarinfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

10. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

11. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

12. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

13. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

14. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

15. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

16. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered nonpathogenic without loss of immunogenicity.

17. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

18. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

19. A vaccine useful in immunizing dogs against kennel cough comprising at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

20. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

21. A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

22. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

23. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

24. A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.
Other info:

Inventors: Emery, Jerrell Bemis (Chalfont, PA, US)
Bittle, James Long (Doylestown, PA, US)

Application Number: 547430
Filing Date: 1975-02-06
Publication_date: 1976-04-13
Assignee: Pitman-Moore, Inc. (Washington Crossing, NJ)
Primary Class(es): 424/201.1 424/202.1, 424/211.1, 424/233.1, 424/253.1, 435/237, 435/245
Other Classes:
US Patent Ref:
Other Refs: Other References: binn et al., P.S.E.B.M. 126: 140-145 (1967), "Viruses Recovered from Laboratory Dogs with Respiratory Disease".
Rosenberg et al., FEDN. Proc. 29, 636, (Apr, 15, 1970), "A Canine Parainfluenza Virus, Its Role in Respiratory Disease in Dogs."
Bittle et al., J.A.V.M.A., 156, (12 pt.1): 1771-1773, June 15, 1970, "The Epizootiology of Canine Parainfluenza".
Binn et al., J.A.V.M.A. 156, (12, pt.1): 1774-1777, June 15, 1970, "Comments on Epizootiology of Parainfluenza SV-5 in Dogs".
Appel et al. J.A.V.M. 156, (12, pt.1): 1778-1781, June 15, 1970, "SV-5-like Parainfluenza in Dogs."
Tribe et al., J. Small Anim. Pract. 14, (5): 251-255, May, 1973, "Protection of Dogs Against Canine Hepatitis With Toronto, A26/61 Virus, (Kennel Cough Isolate), Hexon Antigen."